Novo Holdings reports Total Income and Investment Returns of DKK 31 billion (€4.2 billion) for 2023. Total Assets grow by 38% to DKK 1,114 billion (€149 billion)

/PRNewswire/ -- Novo Holdings today announced its financial results for 2023*. Strong Investment Portfolio performance, and growth of the Novo Group companies...

Related Keywords

Denmark ,United States ,Copenhagen ,Køavn ,Wuxi ,Jiangsu ,China ,Singapore ,Hong Kong ,America ,Danish ,Limmatech Biologics ,Kasim Kutay ,Hillstar Bio ,Novo Nordisk ,Oxford Biomedica ,Acesion Pharma ,Terremoto Biosciences ,Contract Development ,Pureos Bioventures Fund ,Impact Fund ,Novo Holding ,Novo Holdings ,Novo Group ,Scion Fundi Venture Investments ,Novo Group Companies ,Biogeneration Capital Fund ,Novo Nordisk Foundation ,Value Of The Holding ,Novo Holdings Investment Portfolio ,Manufacturing Organisation ,Paratek Pharmaceuticals ,Octave Health ,Strong Investment Portfolio ,Total Income ,Investment Returns ,Investment Portfolio ,Total Investment Return ,Total Assets ,Life Science Investments ,Seed Investments ,Venture Investments ,Bioindustrial Investments ,Asia Investments ,Growth Investments ,Principal Investments ,Capital Investments ,Glentra Capital ,Special Investments ,Alentis Therapeutics ,Lexeo Therapeutics ,Manat Bio ,Maplight Therapeutics ,Ray Therapeutics ,Scion Fund ,Hemab Therapeutics ,Seed Investment ,Gurnet Point ,Deep Branch ,Lepure Biotech ,Total Investment ,Total Value ,Total Holdings ,Investment Assets ,Internal Rate ,Time Weighted Returns ,